After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.